Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Transl Res. 2020 Nov;225:70-81. doi: 10.1016/j.trsl.2020.04.006. Epub 2020 May 12.
Antiphospholipid syndrome is one of the more common acquired causes of hypercoagulability. Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia). Classification criteria include 3 different antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Management includes both preventive strategies (low-dose aspirin, hydroxychloroquine) and long-term anticoagulation after thrombosis.
抗磷脂综合征是较为常见的获得性高凝状态病因之一。其主要表现为血栓形成(动脉、静脉或微血管)和妊娠并发症(流产、晚期宫内胎儿死亡和严重子痫前期)。分类标准包括 3 种不同的抗磷脂抗体:狼疮抗凝物、抗心磷脂抗体和抗β2 糖蛋白 I 抗体。治疗包括预防策略(小剂量阿司匹林、羟氯喹)和血栓形成后的长期抗凝治疗。
Transl Res. 2020-5-12
Drugs Today (Barc). 2010-1
Curr Rheumatol Rep. 2002-10
Arterioscler Thromb Vasc Biol. 2009-3
Thromb Res. 2017-3
Expert Rev Cardiovasc Ther. 2009-12
Expert Opin Ther Targets. 2010-12
Curr Opin Nephrol Hypertens. 2001-3
Basic Clin Pharmacol Toxicol. 2025-8
Mol Med Rep. 2025-4
Int J Mol Med. 2025-2
Microorganisms. 2024-8-19
Adv Chronic Kidney Dis. 2019-9
Cochrane Database Syst Rev. 2019-10-30
Z Gerontol Geriatr. 2020-8
Arthritis Rheumatol. 2020-1
Lupus Sci Med. 2019-3-30